Official SEC submissions

Inhibikase Therapeutics SEC Filings

Direct answer

Inhibikase Therapeutics's latest SEC filing is 8-K.

It was filed on September 8, 2026, and 40 recent filings are available.
Each row links directly to the SEC document and filing index.
Official SEC EDGAR submissions

Get free Inhibikase Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Recent SEC filings

8-K

Current report

Filed:

Report date:

8-K

Open SEC documentView filing index

8-K

Current report

Filed:

Report date:

8-K

Open SEC documentView filing index

10-Q

Periodic report

Filed:

Report date:

10-Q

Open SEC documentView filing index

8-K

Current report

Filed:

Report date:

8-K

Open SEC documentView filing index

4

Insider transaction

Filed:

Report date:

Open SEC documentView filing index

4

Insider transaction

Filed:

Report date:

4

Open SEC documentView filing index

8-K

Current report

Filed:

Report date:

8-K

Open SEC documentView filing index

8-K

Current report

Filed:

Report date:

8-K

Open SEC documentView filing index

8-K

Current report

Filed:

Report date:

8-K

Open SEC documentView filing index

4

Insider transaction

Filed:

Report date:

4

Open SEC documentView filing index

4

Insider transaction

Filed:

Report date:

4

Open SEC documentView filing index

4

Insider transaction

Filed:

Report date:

4

Open SEC documentView filing index

4

Insider transaction

Filed:

Report date:

4

Open SEC documentView filing index

4

Insider transaction

Filed:

Report date:

4

Open SEC documentView filing index

4

Insider transaction

Filed:

Report date:

4

Open SEC documentView filing index

8-K

Current report

Filed:

Report date:

8-K

Open SEC documentView filing index

10-Q

Periodic report

Filed:

Report date:

10-Q

Open SEC documentView filing index

8-K

Current report

Filed:

Report date:

8-K

Open SEC documentView filing index

DEFA14A

Proxy statement

Filed:

DEFA14A

Open SEC documentView filing index

DEF 14A

Proxy statement

Filed:

Report date:

DEF 14A

Open SEC documentView filing index

8-K

Current report

Filed:

Report date:

8-K

Open SEC documentView filing index

10-K

Periodic report

Filed:

Report date:

10-K

Open SEC documentView filing index

8-K

Current report

Filed:

Report date:

8-K

Open SEC documentView filing index

4

Insider transaction

Filed:

Report date:

4

Open SEC documentView filing index

4

Insider transaction

Filed:

Report date:

4

Open SEC documentView filing index

4

Insider transaction

Filed:

Report date:

4

Open SEC documentView filing index

4

Insider transaction

Filed:

Report date:

4

Open SEC documentView filing index

4

Insider transaction

Filed:

Report date:

4

Open SEC documentView filing index

4

Insider transaction

Filed:

Report date:

4

Open SEC documentView filing index

8-K

Current report

Filed:

Report date:

8-K

Open SEC documentView filing index

4

Insider transaction

Filed:

Report date:

PRIMARY DOCUMENT

Open SEC documentView filing index

8-K

Current report

Filed:

Report date:

8-K

Open SEC documentView filing index

8-K

Current report

Filed:

Report date:

8-K

Open SEC documentView filing index

10-Q

Periodic report

Filed:

Report date:

10-Q

Open SEC documentView filing index

8-K

Current report

Filed:

Report date:

8-K

Open SEC documentView filing index

4

Insider transaction

Filed:

Report date:

4

Open SEC documentView filing index

10-Q

Periodic report

Filed:

Report date:

10-Q

Open SEC documentView filing index

8-K

Current report

Filed:

Report date:

8-K

Open SEC documentView filing index

4/A

Insider transaction

Filed:

Report date:

4/A

Open SEC documentView filing index

4/A

Insider transaction

Filed:

Report date:

4/A

Open SEC documentView filing index

Verified data

Recent filing categories
4
Recent filings
40
SEC CIK
0001750149
Latest filing date
September 8, 2026

Explore related company data

View the Inhibikase Therapeutics company profileView Inhibikase Therapeutics annual financials